secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001104659-24-034674
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents reports 10% core sales growth; plans DrugSorb-ATR submission in H2 2024
--------------------------------------------------------------------------------

- FY2023 total revenue $36.3M (+5% YoY); core CytoSorb sales $31.0M (+10%).
- Product gross margin improved to 72% from 70%; expects 75-80% in 2024.
- STAR-T trial selected for Breakout Presentation at AATS (April 2024); FDA/Health Canada submission planned for H2 2024.
- Ended 2023 with $15.6M cash; cost cuts include 15% RIF; cash runway into Q4 2024.
- Entered India partnership with Eris Lifesciences; plan to launch PuriFi pump in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924034674/0001104659-24-034674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924034674/tm248917d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-034674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer